These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20624171)

  • 1. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease.
    Yilmaz Y; Eren F; Yonal O; Kurt R; Aktas B; Celikel CA; Ozdogan O; Imeryuz N; Kalayci C; Avsar E
    Eur J Clin Invest; 2010 Oct; 40(10):887-92. PubMed ID: 20624171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
    Li H; Fang Q; Gao F; Fan J; Zhou J; Wang X; Zhang H; Pan X; Bao Y; Xiang K; Xu A; Jia W
    J Hepatol; 2010 Nov; 53(5):934-40. PubMed ID: 20675007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently.
    Li X; Fan X; Ren F; Zhang Y; Shen C; Ren G; Sun J; Zhang N; Wang W; Ning G; Yang J
    Diabetes Res Clin Pract; 2011 Jul; 93(1):10-6. PubMed ID: 21596453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
    Schreuder TC; Marsman HA; Lenicek M; van Werven JR; Nederveen AJ; Jansen PL; Schaap FG
    Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G440-5. PubMed ID: 20093562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis.
    Yilmaz Y; Eren F; Ayyildiz T; Colak Y; Kurt R; Senates E; Tuncer I; Dolar E; Imeryuz N
    Clin Chim Acta; 2011 Nov; 412(23-24):2296-9. PubMed ID: 21888902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis.
    Yilmaz Y; Yonal O; Kurt R; Ari F; Oral AY; Celikel CA; Korkmaz S; Ulukaya E; Ozdogan O; Imeryuz N; Avsar E; Kalayci C
    Ann Clin Biochem; 2010 Nov; 47(Pt 6):549-53. PubMed ID: 20926473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China.
    Li H; Dong K; Fang Q; Hou X; Zhou M; Bao Y; Xiang K; Xu A; Jia W
    J Hepatol; 2013 Mar; 58(3):557-63. PubMed ID: 23142063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease.
    Eren F; Kurt R; Ermis F; Atug O; Imeryuz N; Yilmaz Y
    Clin Biochem; 2012 Jun; 45(9):655-8. PubMed ID: 22465275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
    Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.
    Mraz M; Bartlova M; Lacinova Z; Michalsky D; Kasalicky M; Haluzikova D; Matoulek M; Dostalova I; Humenanska V; Haluzik M
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):369-75. PubMed ID: 19702724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance.
    Yilmaz Y; Ulukaya E; Atug O; Dolar E
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1247-51. PubMed ID: 19474742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD).
    Madan K; Bhardwaj P; Thareja S; Gupta SD; Saraya A
    J Clin Gastroenterol; 2006; 40(10):930-5. PubMed ID: 17063114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease.
    Yilmaz Y; Eren F; Colak Y; Senates E; Celikel CA; Imeryuz N
    Scand J Gastroenterol; 2012 Dec; 47(12):1488-93. PubMed ID: 23137022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma interleukin-18/interleukin-18 binding protein ratio in Chinese with NAFLD.
    Li Y; Li-Li Z; Qin L; Ying W
    Hepatogastroenterology; 2010; 57(97):103-6. PubMed ID: 20422882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.
    Uchil D; Pipalia D; Chawla M; Patel R; Maniar S; Narayani ; Juneja A
    J Assoc Physicians India; 2009 Mar; 57():201-4. PubMed ID: 19588647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis.
    Konopelska S; Kienitz T; Hughes B; Pirlich M; Bauditz J; Lochs H; Strasburger CJ; Stewart PM; Quinkler M
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):554-60. PubMed ID: 18665910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.
    Dushay J; Chui PC; Gopalakrishnan GS; Varela-Rey M; Crawley M; Fisher FM; Badman MK; Martinez-Chantar ML; Maratos-Flier E
    Gastroenterology; 2010 Aug; 139(2):456-63. PubMed ID: 20451522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease.
    Aigner E; Strasser M; Haufe H; Sonnweber T; Hohla F; Stadlmayr A; Solioz M; Tilg H; Patsch W; Weiss G; Stickel F; Datz C
    Am J Gastroenterol; 2010 Sep; 105(9):1978-85. PubMed ID: 20407430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Association of serum leptin and insulin resistance with nonalcoholic fatty liver disease].
    Hu ZW; Guo JW; Deng XL
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):853-5. PubMed ID: 16793619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.